Patient-Friendly Explanation
Pemvidutide is an investigational weight loss medication that mimics two natural hormones — GLP-1 and glucagon. By activating both pathways, it helps reduce appetite while also increasing the amount of energy your body burns at rest.
Clinical Definition
Pemvidutide is a dual GLP-1/glucagon receptor agonist developed by Altimmune. Glucagon receptor activation increases energy expenditure and promotes fat oxidation, while GLP-1 agonism suppresses appetite and delays gastric emptying. Phase 2 clinical trials have demonstrated significant weight loss with a favourable impact on liver fat and lipid profiles.
Why It Matters
Dual agonist medications like pemvidutide represent the next frontier in obesity pharmacotherapy, targeting both sides of the energy balance equation. NuLifeCare Singapore monitors emerging treatments to provide patients with the most current information about their weight management options.